Please login to the form below

Not currently logged in
Email:
Password:

London Genetics senior appointments

London Genetics has made three appointments to its board and management team

London Genetics, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of genetics research, has made three appointments to its board and management team.

Dr Barrie Ward has been appointed as chairman to drive the next phase of the company's growth as the importance of pharmacogenetics in drug development increases. He previously held senior positions at GSK R&D and various biotechnology companies in the US and UK.

In addition, Dominique Kleyn has been brought on as CEO and Dr Mark Caulfield has been appointed clinical director. Kleyn previously held leadership roles at Imperial College London and within the biotech sector; Caulfield is an expert in the genetics of cardiovascular disease, particularly hypertension. He is director of the William Harvey Research Institute at Bart's and the London School of Medicine and Dentistry at Queen Mary, University of London.

Commenting on his appointment, Dr Ward said: "I am delighted to have joined the strong team at London Genetics at a time when the importance of pharmacogenetics in drug development is becoming increasingly clear. This is a pivotal phase of the company's development as it works in partnership with biopharmaceutical companies to add value to drug development programmes."

Ms Kleyn added: "We have an exciting partnering programme lined up for the coming months and I look forward to working together with our founding institutions and the biopharmaceutical industry to build interactions that will help to make a difference to drug development."

London Genetics has broad therapeutic experience with a particular focus on cardiovascular drugs and cardiovascular safety.

22nd September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics